KIORA PHARMACEUTICALS INCKPRX

KIORA PHARMACEUTICALS INC Segments Disclosure

10-KFiled Mar 25, 20262 min read
Segment Information
The Company operates in and reports as a single reportable segment, focused on the development of innovative ophthalmic pharmaceutical products.
Our CODM is our President and Chief Executive Officer, Brian M. Strem. The CODM does not evaluate profitability nor evaluate performance or allocate resources below the level of the consolidated Company. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM reviews operating expenses and net (loss) income presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. These metrics serve as benchmarks to evaluate the business, measure performance, identify trends, prepare financial projections, and make strategic decisions. The CODM does not evaluate performance or allocate resources based on segment assets data; therefore, total segment assets are not presented.
The following table presents the revenue, significant expenses, and net (loss) income for the Company’s single reportable segment:
Year Ended December 31,
20252024
Total Revenue$— $16,020,000 
Less: Significant and Other Segment Expenses
General and Administrative5,745,087 5,542,324 
Research and Development
KIO-10117,541 25,456 
KIO-104718,552 671,739 
KIO-201*— 30,875 
KIO-3017,217,067 3,836,105 
R&D Tax Credit(587,447)17,894 
Unallocated Research and Development Expenses23,414,684 3,260,138 
Total Research & Development10,780,397 7,842,207 
KIO-301 Collaboration Credit(7,066,237)(2,945,350)
In-Process R&D Impairment4,624,000 2,008,000 
Change in Fair Value of Contingent Consideration(1,252,174)(937,469)
Interest Income(894,002)(1,252,849)
Other Segment Expenses3180,232 103,399 
Income Tax (Benefit) Expense(1,282,149)2,065,005 
Net (Loss) Income$(10,835,154)$3,594,733 
Unallocated research and development expenses primarily include personnel costs, research consulting and scientific advisory expenses.
3 Other segment expenses primarily include interest expense, other income (expense), net, and loss on disposal of fixed assets.

Historical Timeline

Fiscal YearFiled
2025Mar 25, 2026Showing above
2024Mar 25, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueFair ValuePP&EGoodwill & IntangiblesDebtCommitmentsStock CompensationNew Standards